Akums reports Q1 FY26 PAT at Rs. 65 Cr
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
The companies will now begin detailed contract negotiations and proceed with necessary consultations and approval processes
A global platform advancing pharmaceutical collaboration, innovation, and exports—powering healthcare and connecting markets worldwide
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
This certification validates the plant’s robust capabilities in manufacturing a wide range of sterile dosage forms
Upgrades 2025 full-year CDMO sales and margin outlook
Reported EBITDA up by 19% year-on-year with reported EBITDA margin at 25%
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Subscribe To Our Newsletter & Stay Updated